Zhen Hou1, Shuangshuang Li2, Wei Ren2, Juan Liu2, Jing Yan2, Suiren Wan1. 1. State Key Laboratory of Bioelectronics, Laboratory for Medical Electronics, School of Biological Sciences and Medical Engineering, Southeast University, Nanjing 210096, China. 2. The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing 210000, China.
Abstract
BACKGROUND: To investigate the capability of radiomic analysis using T2-weighted (T2W) and spectral attenuated inversion-recovery T2-weighted (SPAIR T2W) magnetic resonance imaging (MRI) for predicting the therapeutic response of esophageal squamous cell carcinoma (ESCC) to chemoradiotherapy (CRT). METHODS: Pretreatment T2W- and SPAIR T2W-MRI of 68 ESCC patients (37 responders, 31 nonresponders) were analyzed. A number of 138 radiomic features were extracted from each image sequence respectively. Kruskal-Wallis test were performed to evaluate the capability of each feature on treatment response classification. Sensitivity and specificity for each of the studied features were derived using receiver operating characteristic (ROC) analysis. Support vector machine (SVM) and artificial neural network (ANN) models were constructed based on the training set (23 responders, 20 nonresponders) for the prediction of treatment response, and then the testing set (14 responders, 11 nonresponders) validated the reliability of the models. Comparison between the performances of the models was performed by using McNemar's test. RESULTS: Radiomic analysis showed significance in the prediction of treatment response. The analyses showed that complete responses (CRs) versus stable diseases (SDs), partial responses (PRs) versus SDs, and responders (CRs and PRs) versus nonresponders (SDs) could be differentiated by 26, 17, and 33 features (T2W: 11/11/15, SPAIR T2W: 15/6/18), respectively. The prediction models (ANN and SVM) based on features extracted from SPAIR T2W sequence (SVM: 0.929, ANN: 0.883) showed higher accuracy than those derived from T2W (SVM: 0.893, ANN: 0.861). No statistical difference was observed in the performance of the two classifiers (P=0.999). CONCLUSIONS: Radiomic analysis based on pretreatment T2W- and SPAIR T2W-MRI can be served as imaging biomarkers to predict treatment response to CRT in ESCC patients.
BACKGROUND: To investigate the capability of radiomic analysis using T2-weighted (T2W) and spectral attenuated inversion-recovery T2-weighted (SPAIR T2W) magnetic resonance imaging (MRI) for predicting the therapeutic response of esophageal squamous cell carcinoma (ESCC) to chemoradiotherapy (CRT). METHODS: Pretreatment T2W- and SPAIR T2W-MRI of 68 ESCC patients (37 responders, 31 nonresponders) were analyzed. A number of 138 radiomic features were extracted from each image sequence respectively. Kruskal-Wallis test were performed to evaluate the capability of each feature on treatment response classification. Sensitivity and specificity for each of the studied features were derived using receiver operating characteristic (ROC) analysis. Support vector machine (SVM) and artificial neural network (ANN) models were constructed based on the training set (23 responders, 20 nonresponders) for the prediction of treatment response, and then the testing set (14 responders, 11 nonresponders) validated the reliability of the models. Comparison between the performances of the models was performed by using McNemar's test. RESULTS: Radiomic analysis showed significance in the prediction of treatment response. The analyses showed that complete responses (CRs) versus stable diseases (SDs), partial responses (PRs) versus SDs, and responders (CRs and PRs) versus nonresponders (SDs) could be differentiated by 26, 17, and 33 features (T2W: 11/11/15, SPAIR T2W: 15/6/18), respectively. The prediction models (ANN and SVM) based on features extracted from SPAIR T2W sequence (SVM: 0.929, ANN: 0.883) showed higher accuracy than those derived from T2W (SVM: 0.893, ANN: 0.861). No statistical difference was observed in the performance of the two classifiers (P=0.999). CONCLUSIONS: Radiomic analysis based on pretreatment T2W- and SPAIR T2W-MRI can be served as imaging biomarkers to predict treatment response to CRT in ESCC patients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Balaji Ganeshan; Vicky Goh; Henry C Mandeville; Quan Sing Ng; Peter J Hoskin; Kenneth A Miles Journal: Radiology Date: 2012-11-20 Impact factor: 11.105
Authors: Frederic G Dhermain; Peter Hau; Heinrich Lanfermann; Andreas H Jacobs; Martin J van den Bent Journal: Lancet Neurol Date: 2010-08-10 Impact factor: 44.182
Authors: Francesco De Cobelli; Francesco Giganti; Elena Orsenigo; Michaela Cellina; Antonio Esposito; Giulia Agostini; Luca Albarello; Elena Mazza; Alessandro Ambrosi; Carlo Socci; Carlo Staudacher; Alessandro Del Maschio Journal: Eur Radiol Date: 2013-04-16 Impact factor: 5.315
Authors: Sophie E Heethuis; Peter S N van Rossum; Irene M Lips; Lucas Goense; Francine E Voncken; Onne Reerink; Richard van Hillegersberg; Jelle P Ruurda; Marielle E Philippens; Marco van Vulpen; Gert J Meijer; Jan J W Lagendijk; Astrid L H M W van Lier Journal: Radiother Oncol Date: 2016-06-10 Impact factor: 6.280
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Benjamin W Wormald; Simon J Doran; Thomas Ej Ind; James D'Arcy; James Petts; Nandita M deSouza Journal: Gynecol Oncol Date: 2019-11-02 Impact factor: 5.482